Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

Background C225 is an antibody to the epidermal growth factor receptor (EGFR), and inhibits growth of various tumour cells. The antibody is currently being used as a therapeutic agent in several clinical trials of patients with carcinomas.Objectives To determine and investigate the cutaneous side‐ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2001-06, Vol.144 (6), p.1169-1176
Hauptverfasser:	Busam, K.J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., Halpern, A.C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Agents - adverse effects Biological and medical sciences C225 Carcinoma, Renal Cell - therapy Cell Cycle Proteins Cetuximab Cyclin-Dependent Kinase Inhibitor p27 Drug Eruptions - etiology Drug Eruptions - metabolism Drug Eruptions - pathology Drug toxicity and drugs side effects treatment epidermal growth factor receptor ErbB Receptors - antagonists & inhibitors ErbB Receptors - immunology Female folliculitis Folliculitis - chemically induced Humans Immunoenzyme Techniques Kidney Neoplasms - therapy Male Medical sciences Microtubule-Associated Proteins - metabolism Middle Aged Pharmacology. Drug treatments Recombinant Fusion Proteins - adverse effects Severity of Illness Index Toxicity: skin, dermoskeleton Tumor Suppressor Proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!